ArticleAdvances in virology2011
Bimolecular Complementation to Visualize Filovirus VP40-Host Complexes in Live Mammalian Cells: Toward the Identification of Budding Inhibitors.
Article in Advances in virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Exploring the druggability of the UEV domain of human TSG101 in search for broad-spectrum antivirals.Protein science : a publication of the Protein Society · 2025Article
- Article
- Compound FC-10696 Inhibits Egress of Marburg Virus.Antimicrobial agents and chemotherapy · 2021Article
- Review
- Angiomotin regulates budding and spread of Ebola virus.The Journal of biological chemistry · 2020Article
- Modular mimicry and engagement of the Hippo pathway by Marburg virus VP40: Implications for filovirus biology and budding.PLoS pathogens · 2020Article
- Current status of small molecule drug development for Ebola virus and other filoviruses.Current opinion in virology · 2019Review
- Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules.Annual reports in medicinal chemistry · 2018Article
- Ubiquitin Ligase WWP1 Interacts with Ebola Virus VP40 To Regulate Egress.Journal of virology · 2017Article
- Chaperone-Mediated Autophagy Protein BAG3 Negatively Regulates Ebola and Marburg VP40-Mediated Egress.PLoS pathogens · 2017Article
- ITCH E3 Ubiquitin Ligase Interacts with Ebola Virus VP40 To Regulate Budding.Journal of virology · 2016Article
- Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress.Bioorganic & medicinal chemistry letters · 2016Article
- Development of Small-Molecule Antivirals for Ebola.Medicinal research reviews · 2015Review
- Interaction with Tsg101 is necessary for the efficient transport and release of nucleocapsids in marburg virus-infected cells.PLoS pathogens · 2014Article
- Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.Journal of virology · 2014Article
- A host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress.Journal of virology · 2014Article
- Could the Ebola virus matrix protein VP40 be a drug target?Expert opinion on therapeutic targets · 2014Article
- Host IQGAP1 and Ebola virus VP40 interactions facilitate virus-like particle egress.Journal of virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Virus-host interactions play key roles in promoting efficient egress of many RNA viruses, including Ebola virus (EBOV or "e") and Marburg virus (MARV or "m"). Late- (L-) domains conserved in viral matrix proteins recruit specific host proteins, such as Tsg101 and Nedd4, to facilitate the budding process. These interactions serve as attractive targets for the development of broad-spectrum budding inhibitors. A major gap still exists in our understanding of the mechanism of filovirus budding due to the difficulty in detecting virus-host complexes and mapping their trafficking patterns in the natural environment of the cell. To address this gap, we used a bimolecular complementation (BiMC) approach to detect, localize, and follow the trafficking patterns of eVP40-Tsg101 complexes in live mammalian cells. In addition, we used the BiMC approach along with a VLP budding assay to test small molecule inhibitors identified by in silico screening for their ability to block eVP40 PTAP-mediated interactions with Tsg101 and subsequent budding of eVP40 VLPs. We demonstrated the potential broad spectrum activity of a lead candidate inhibitor by demonstrating its ability to block PTAP-dependent binding of HIV-1 Gag to Tsg101 and subsequent egress of HIV-1 Gag VLPs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.